Abstract
ImmunoPET is a non-invasive imaging technology based on tracking and quantification of radiolabeled monoclonal antibodies, antibody fragments and peptides in vivo. The knowledge of distribution and expression levels of a given receptor is a key for successful receptor targeted cancer therapy. ImmunoPET performed with probes with high affinity and specificity to a given receptor aspires to be a method for obtaining comprehensive information about current in vivo status of the targeted receptor. This review describes methods for radiolabeling of peptides, monoclonal antibodies, and antibody fragments for immunoPET and highlights the recently reported pre-clinical and clinical applications of immunoPET in receptor targeted therapy.
Keywords: Imaging technology, immunoPET, monoclonal antibodies, radiolabeling, receptor targeted therapy, THIOMAB, trastuzumab, HER2, Herceptin, antibody-drug conjugates, ADC, single photon computed tomography, positron emission tomography, PET, 4-fluorobenzoic acid (FBA), 2-fluoropropionic acid (FPA), N-succinimidyl 4-fluorobenzoate, SFB, hydrazinonicotinic acid, copper-I catalyzed 1,3- dipolar cycloaddition, CuAAC, N-succinimidyl 3-iodobenzoate, SIB, 1-2 desferrioxamine, Zevalin, Epidermal Growth Factor Receptor, cetuximab, panitumumab, gefitinib, erlotinib, hEGF
Current Drug Delivery
Title: Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Volume: 8 Issue: 1
Author(s): Jan Marik and Jagath R. Junutula
Affiliation:
Keywords: Imaging technology, immunoPET, monoclonal antibodies, radiolabeling, receptor targeted therapy, THIOMAB, trastuzumab, HER2, Herceptin, antibody-drug conjugates, ADC, single photon computed tomography, positron emission tomography, PET, 4-fluorobenzoic acid (FBA), 2-fluoropropionic acid (FPA), N-succinimidyl 4-fluorobenzoate, SFB, hydrazinonicotinic acid, copper-I catalyzed 1,3- dipolar cycloaddition, CuAAC, N-succinimidyl 3-iodobenzoate, SIB, 1-2 desferrioxamine, Zevalin, Epidermal Growth Factor Receptor, cetuximab, panitumumab, gefitinib, erlotinib, hEGF
Abstract: ImmunoPET is a non-invasive imaging technology based on tracking and quantification of radiolabeled monoclonal antibodies, antibody fragments and peptides in vivo. The knowledge of distribution and expression levels of a given receptor is a key for successful receptor targeted cancer therapy. ImmunoPET performed with probes with high affinity and specificity to a given receptor aspires to be a method for obtaining comprehensive information about current in vivo status of the targeted receptor. This review describes methods for radiolabeling of peptides, monoclonal antibodies, and antibody fragments for immunoPET and highlights the recently reported pre-clinical and clinical applications of immunoPET in receptor targeted therapy.
Export Options
About this article
Cite this article as:
Marik Jan and R. Junutula Jagath, Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663589
DOI https://dx.doi.org/10.2174/156720111793663589 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene
Letters in Drug Design & Discovery EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science Molecular Targeted Therapies in the Management of Head and Neck Squamous Cell Carcinoma: Recent Developments and Perspectives
Anti-Cancer Agents in Medicinal Chemistry Application of Chitosan and Propolis in Endodontic Treatment: A Review
Mini-Reviews in Medicinal Chemistry One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Editorial
Reviews on Recent Clinical Trials Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Atoh1: Landscape for Inner Ear Cell Regeneration
Current Gene Therapy PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy
Current Gene Therapy Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Immunomodulatory Activity of Astragalus, Ginseng and Echinacea: From Keith Block and Mark Mead to Today, Have We Moved On?
Current Immunology Reviews (Discontinued) Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine